Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27439561 | 1.00 | MMP1 (0.47) | MMP1MMP3MMP9ITGA4ITGB7 | |
| SCHEMBL5650826 | 1.00 | MMP1 (0.47) | MMP1MMP3MMP9ITGA4ITGB7 | |
| SCHEMBL27610061 | 0.86 | CTSS (0.52) | MMP1MMP3MMP9CTSSCTSK | |
| SCHEMBL23789725 | 0.84 | ITGA4 (0.50) | MMP1MMP3MMP9ITGA4ITGB7 | |
| SCHEMBL5651688 | 0.84 | MMP8 (0.51) | POLBMAPTSRRSMN1; SMN2 | |
| SCHEMBL5651363 | 0.84 | MMP8 (0.51) | POLBMAPTSRRSMN1; SMN2 | |
| SCHEMBL8442322 | 0.82 | LTA4H (0.47) | CTSSCTSKCTSLCTSBTDP1 | |
| SCHEMBL10420967 | 0.82 | LTA4H (0.47) | CTSSCTSKCTSLCTSBTDP1 | |
| SCHEMBL5667024 | 0.79 | ITGA4 (0.46) | MMP1MMP3MMP9ITGA4ITGB7 | |
| SCHEMBL27877867 | 0.79 | MMP1 (0.45) | MMP1MMP3MMP9ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104447394-B | Novel synthesis process of ubenimex | 成都傲飞生物化学品有限责任公司 | 2017-01-18 | — | — | CN | disclosed |
| US-7307184-B2 | Processes for preparing oxazolidinone derivatives of β-hydroxyethlamine compounds and for preparing β-hydroxyethlamine compounds | KANEKA CORPORATION (JP) | 2007-12-11 | — | — | US | disclosed |
| US-20040181074-A1 | Process for producing oxazolidinone derivative of beta-hydroxyethylamine compound and for producing beta-hydroxyethlamine compound | KANEKA CORPORATION (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20040049074-A1 | Process for producing 3-amino-2-hydroxypropionic acid derivatives | KANEKA CORPORATION (JP) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049074-A1 | Process for producing 3-amino-2-hydroxypropionic acid derivatives | AASDHPPT, HPD, HAAO | MMP1 4351/4885MMP3 1805/4885MMP9 2672/4885 |
| US-20040181074-A1 | Process for producing oxazolidinone derivative of beta-hydroxyethylamine compound and for producing beta-hydroxyethlamine compound | HNMT, PNMT, HRH4 | MMP1 3808/4885MMP3 4259/4885MMP9 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.